Skip to main content
 

Commercial development of my research discoveries: Still more personal stories from former NIH intramural scientists

Monday, September 22, 2014 — Concurrent Symposia Session I

2:00 p.m. – 4:00 p.m.

Classroom 3

Co-chairs

  • Steven Ferguson, OD
  • Todd Chappell, OD

Program

Long before programs supporting translational science came to NIH, intramural investigators often fulfilled their vision of achieving translational and public health goals for their research by leaving NIH to start or co-found their own companies. By practicing translational science of the "DIY (do-it-yourself) variety" these investigators were able to achieve major personal, scientific and professional goals -- and yet still obtain both important clinical and economic results for their science. In Maryland alone over 50 of the founders of Maryland bioscience/biomedical companies spent some time as intramural investigators. Without this talent from the NIH intramural program, Maryland would not have one of the top concentrations of bioscience/biomedical companies in the country. This mini-symposium will again feature presentations from a variety of distinguished former NIH intramural scientists who became company founders and will share the story of their science and passion for bringing it forward for development. The program was originally organized for the 2013 Research Festival but was unable to be rescheduled after the government shutdown.

Trophogen, Inc. - Development of High Affinity Glycoprotein Hormones and related Analogs for Human and Animal Reproductive Health
Bruce Weintraub, NIDDK

GlyoMimetics, Inc. -- Glycomimetic Drugs, A New Source of Therapeutic Opportunities For Treating Sickle Cell, Cancer, and Other Serious Diseases
John Magnani, NCI

Emergent BioSolutions, Inc. – Using Tools From the NIH to Move to a Career in Industry at Emergent BioSolutions
Veronica Hall, NCI

MacroGenics, Inc. -- Skills and Knowledge Acquired At NIH Which Helped Start My Commercial Sector Career at Medimmune and MacroGenics
Scott Koenig, NIAID

back to top